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In 1906, Alois Alzheimer described the neuropathologyof the disease that was to bear his name.1 Subsequently,
our understanding of Alzheimer disease (AD) has grown
significantly. The autosomal dominant mutations to the
amyloid precursor protein (APP), presenilin (PS) 1, and
PS2 genes that cause early onset AD have been very
informative, leading to the articulation of the amyloid
cascade hypothesis.2–4 This hypothesis has been the basis
for several disease-modifying therapeutic approaches for
AD. This has been partly because it provided a coherent
framework for understanding AD pathogenesis but also
because several pharmacological approaches that targeted
the amyloid peptide (amyloidocentric) were sufficiently
well-founded scientifically to enter clinical development.
In the past 5 years, there have been 6 amyloidocentric
programs that completed phase 3 clinical testing. None
met their primary outcome measures (Table 1), although
1, solanezumab, showed encouraging results in a prespe-
cified secondary outcome measure. This disappointing
track record has brought into question the amyloidocen-
tric therapeutic approach. This review will consider these
programs from the following perspectives:
1. What was the hypothesis being tested?
2. Did the preclinical data offer support for the
hypothesis?
3. Did the clinical program establish that the drug
mediated the desired effect, and how robust were the
phase 2 data that were used to progress to a phase
3 trial?
4. What did the phase 3 trials demonstrate?
AD is responsible for approximately 70% of all
dementias.5 Currently, a confirmed diagnosis of AD
requires the presence of plaques (deposited amyloid b
[Ab] peptide) and tangles (intracellular, aggregated,
hyperphosphorylated, tau protein) found via postmortem
neuropathological examination of the brain. Although
there are many abnormalities within an AD brain, neuro-
nal death, particularly within the hippocampus, entorhi-
nal cortex, and frontal cortical regions, contribute to
cognitive impairment. The amount and regional distribu-
tion of plaques in AD brains does not correlate well with
the extent of neuronal loss or with the clinical severity of
dementia.6 There have been studies suggesting a better
correlation with soluble Ab in AD brain.7 However,
deposited Ab comprises approximately 95% of total Ab
(soluble plus deposited).8 The role of Ab in AD has
been long debated; does it trigger the disease process, is
there some threshold amount that is required to sustain
the disease, or does deposited Ab drive the disease for-
ward in a continuous fashion?9 The presence of tau
pathology, in the form of insoluble paired helical fila-
ments (PHFs), correlates much better both with the areas
of the brain that suffer from neurodegeneration and also
with the extent of cognitive impairment.10,11 However,
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TABLE 1. Outcomes of Phase 3 Clinical Trials of Amyloidocentric Drugs
Drug Name and Proposed
Mechanism of Action
Phase 2 Results Phase 3 Results
Tramiprosate, Ab
aggregation inhibitor.
58 mild–moderate AD patients
randomized to 4 groups: placebo, 50,
100, 150mg/kg tramiprosate b.i.d. for 3
months. Drug mediated a significant
lowering of Ab42 in CSF samples.21
1,052 mild–moderate AD patients
randomized to 3 groups: placebo, 100,
150mg/kg b.i.d. for 78 weeks. No
significant effects on primary outcome
measures on ADAS-cog and CDR-SB.25
Tarenflurbil, c-secretase
modulator.
210 mild–moderate AD patients
randomized to placebo, 400, 800mg
b.i.d. tarenflurbil for 12 months. Some
evidence of an improvement ADCS-ADL
at the 800mg b.i.d. dose.46
1,684 mild AD patients randomized to
placebo, 800mg b.i.d. tarenflurbil for 18
months. No significant effects on
primary outcome measures on ADAS-cog
and ADCS-ADL.47
Semagacestat, c-secretase
inhibitor.
51 mild–moderate AD patients
randomized to placebo, 100, 140mg o.d.
semagacestat following dose escalation for
a total duration of 18 weeks. Significant
reduction in plasma Ab40 peptide.77
2,600 mild–moderate AD patients
randomized to placebo, 100, 140mg
semagacestat o.d. for 76 weeks in 2 trials
(ClinicalTrials.gov identifiers
NCT00594568, NTC00762411). Trials
were halted after interim analysis showed
increased incidence of skin cancer and
worsening of cognition and activities of
daily living.78
Bapineuzumab, humanized
monoclonal antibody
directed at amino acids 1–5
of Ab peptide. Amyloid
plaque clearance mediated
by microglial activation.
234 mild–moderate AD patients,
randomized to placebo, 0.15, 0.5, 1.0, or
2.0mg/kg bapineuzumab i.v. infusions
every 13 weeks for 78 weeks. Some
evidence of an improvement in cognitive
and functional endpoints in study
completers and APOE4 noncarriers.106
4,500 mild–moderate AD patients
randomized to placebo and 0.5mg/kg i.v.
every 13 weeks for 18 months in APOE4
carriers, and randomized to placebo, 0.5,
1.0mg/kg i.v. every 13 weeks for 18
months in APOE4 noncarriers in 4 trials
(ClinicalTrials.gov identifiers
lNCT00575055, NCT00574132,
NCT00676143, NCT00667810). Trials
were halted after completion of 2 trials
demonstrated a failure to meet primary
outcome measures on ADAS-cog and
activities of daily living.109
Solanezumab, humanized
monoclonal antibody
directed at amino acids
16–24 of Ab peptide.
Amyloid plaque clearance
mediated via peripheral
sink mechanism.
52 mild–moderate AD patients were
randomized to placebo, 100mg every 4
weeks, 100mg weekly, 400mg every 4
weeks, 400mg weekly i.v. solanezumab
for 12 weeks. There was a significant
dose-dependent increase in Ab42 peptide
in CSF.132
2,000 mild–moderate AD patients
randomized to placebo and 400mg
solanezumab monthly i.v. for 18 months
(ClinicalTrials.gov identifiers
NCT00905372, NCT00904683). Trials
failed to meet their primary outcome
measures on ADAS-cog and ADCS-
ADL. A secondary analysis of mild AD
patients pooled from both trials showed a
significant effect on cognition.115
Gammagard, intravenous
immunoglobulin.
55 mild–moderate AD patients
randomized to placebo, 0.2, 0.5,
0.8g/kg/4 weeks, or 0.1, 0.25, 0.4g/kg/2
weeks for 24 weeks. There was no
increase in Ab40 peptide in plasma at
any dose.129
Trial data currently unpublished. 390
mild–moderate AD patients randomized
to 0.2g/kg/2 weeks and 0.4g/kg/2 weeks
vs placebo for 18 months
(ClinicalTrials.gov Identifier
NCT00818662). Gammagard failed to
reach its coprimary outcomes of
ADAS-cog and ADCS-ADL.
AD5Alzheimer disease; ADAS-cog5Alzheimer’s Disease Assessment Scale–Cognitive Subscale; ADCS-ADL5Alzheimer’s Dis-
ease Cooperative Study–Activities of Daily Living Inventory; b.i.d.5 twice daily; CDR-SB5Clinical Dementia Rating–Sum of
Boxes; CSF5 cerebrospinal fluid; i.v.5 intravenous; o.d.5 once per day.
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the numbers of PHFs do not account for all the neuronal
loss.6 Finally, brain volume remains the best pathological
correlate of dementia in AD.12
Drug Discovery and Development
Programs
Tramiprosate
WHAT WAS THE HYPOTHESIS BEING TESTED?. There
is extensive literature demonstrating that proteoglycans
bind to Ab peptide and can accelerate the transition of
soluble Ab to a b-sheet structure that is required for the
formation of plaques.13,14 Tramiprosate (3-amino-1-
propanesulfonic acid) is a glycosaminoglycan mimetic
that was discovered in a screen that measured the
heparin-stimulated conversion of soluble Ab40 from a
random coil to the b-sheet structure that is characteristic
of aggregated Ab.15 Tramiprosate was tested for its ability
to bind to soluble Ab and thereby prevent its aggrega-
tion. Mechanistically, this would prevent the accumula-
tion of aggregated Ab and increase the levels of soluble
Ab in AD brain.
DID THE PRECLINICAL DATA OFFER SUPPORT FOR
THE HYPOTHESIS?. The published data on tramipro-
sate are not as comprehensive as might be expected for a
clinical candidate. A 20-fold molar excess of tramiprosate
prevented the conversion of Ab40 from random coil/
alpha helix to b-sheet, as assessed by circular dichroism
spectral analysis. No data were available for Ab42.16
Experiments to determine the interaction between trami-
prosate and Ab were performed using electrospray mass
spectrometry analysis, which provided evidence that tra-
miprosate was able to bind to both Ab40 and Ab42 with
a 10-fold molar excess of drug required to give 50%
binding, a finding that was replicated by others.17 How-
ever, there are no data on binding affinity or dose–
response relationships, and the concentration of Ab and
tramiprosate used were very high for these experiments:
20lM of Ab42 and 200lM of tramiprosate. This con-
trasts with a concentration of soluble Ab42 in human
cerebrospinal fluid (CSF) of 45pM.18 Furthermore, the
relevance of this method to an aqueous phase system is
not known. A more relevant approach was taken where
Ab42 was coated onto microtiter plates and test com-
pounds together with fluorescently labeled Ab42 were
added to assess the potency of tramiprosate to prevent
Ab aggregation.19 Key elements of this assay were vali-
dated using fresh-frozen brain slices taken from AD
brains. In this assay, inhibitory concentration of 50%
(IC50) values of test compounds required to block aggre-
gation of 0.22pM of Ab were calculated. Tramiprosate
was shown to be inactive at the highest concentration
tested (718.6nM); that is, at a 3.2 3 106 molar excess
over Ab. Using similar concentrations of Ab and trami-
prosate as had been used in the mass spectrometry analy-
sis, but conducting the experiment in the aqueous phase,
also failed to demonstrate any activity.20 At a 20-fold
molar excess, tramiprosate was able to inhibit the cell
death caused by 5lM Ab42 applied to primary rat neu-
rons.16 These data are difficult to interpret; there were
no dose–response data, and the protective mechanism
was not explored, so it is not possible to determine
whether this effect was associated with inhibition of Ab
aggregation.
In 8-week-old TgCRND8 mice that carry the
human APP K670N/M671L and V717F mutations, tra-
miprosate was administered subcutaneously (s.c.) daily at
30 or 100mg/kg for 8 weeks.16 The levels of compound
in the brain at the end of this dosing regimen were not
assayed. In a separate experiment, continuous infusion of
14C-tramiprosate for 10 days was used to estimate brain
and plasma levels of drug in rats. At 2 doses, 1 and
10mg/kg/h, tramiprosate demonstrated brain drug levels
of about 1lg/ml (70nM) and 10lg/ml (700nM), respec-
tively. The drug half-life was between 2 and 4 hours in
plasma and 16 hours in brain. However, the concentra-
tions of total rather than free drug were assayed, and it is
not known how these data might compare with the s.c.
bolus administration that was used to determine efficacy.
The efficacy experiment demonstrated a significant
effect on the percentage of the cortex occupied by pla-
ques at 100mg/kg but not at 30mg/kg, and the drug had
no effect on the number of thioflavin S–positive plaques
at either dose. A more complete analysis would have
required a wider range of doses and using one mouse
brain hemisphere for histology and the other for quanti-
tative biochemical analysis of Ab species. Surprisingly,
the levels of soluble plasma Ab40 and Ab42 were both
reduced in a dose-related manner by tramiprosate. A
reduction of circulating levels of Ab is consistent with
some type of facilitated clearance mechanism, although
this was not explored further. A different cohort of
TgCRND8 mice were bred that for unknown reasons
showed a 4- to 5-fold increase in cerebral Ab levels. In
these mice, 9-week administration of 500mg/kg/day tra-
miprosate (a much larger dose) resulted in significant
reductions in brain of both soluble and insoluble Ab40
and Ab42 peptides, data that are difficult to reconcile for
an antiaggregation mechanism.
The preclinical data provided some support for an
effect of tramiprosate on Ab levels in brain, but the data
were incomplete. An experimental design that incorpo-
rated a range of drug doses, mice analyzed at different
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times, histological and biochemical analysis performed
simultaneously, and analysis of free and total drug levels
would have provided a clearer picture of the therapeutic
potential of the drug. Target engagement was not
assayed; there was no detection of Ab/tramiprosate com-
plexes. The use of different doses in mice for histology
and biochemistry, and the use of different mouse Ab
phenotypes for the 2 experiments, do not assist interpre-
tation. These data would have confirmed or refuted the
mechanistic hypothesis that at the administered doses tra-
miprosate binds to Ab and prevents aggregation.
PRECLINICAL TO CLINICAL TRANSLATION. In the
phase 2 program, tramiprosate was administered at 50,
100, and 150mg twice daily (b.i.d.) for 3 months to
mild–moderate AD patients with a Mini-Mental State
Examination (MMSE) scores between 13 and 25.21 It is
not possible to determine how these doses were com-
puted from the preclinical studies.
DID THE CLINICAL PROGRAM ESTABLISH THAT
THE DRUG WAS MEDIATING THE DESIRED
EFFECT, AND HOW ROBUST WERE THE PHASE 2
DATA THAT WERE USED TO PROGRESS TO A PHASE
3 TRIAL?. Tramiprosate exposure did not increase in a
dose-proportional manner between the 100 and 150mg
b.i.d. dosing regimens. At 5 hours postdose, CSF samples
were taken, and tramiprosate could be detected in 60%
of patients at between 18 and 50nM. The concentration
of total Ab in CSF is approximately 1nM,22 and thus it
is likely that tramiprosate achieved the 20-fold molar
excess demonstrated to be required to bind to Ab in
some of the in vitro studies. However, it was not demon-
strated whether tramiprosate/Ab complexes were found
in the CSF. Furthermore, some data suggest that Ab con-
centrations in the extracellular space in the brain paren-
chyma might be as much as 100-fold greater than that
found in CSF,9 which would mean that efficacious levels
of tramiprosate may not have been achieved.
Nonetheless, there was a striking dose-dependent
reduction in CSF Ab42 levels of up to 70% after 3
months of treatment, with greater reductions seen in the
mild AD population. If this reduction were seen in a
therapeutic approach that was designed to inhibit Ab
production, it would have been an encouraging sign of
efficacy and proof of mechanism. In AD, a reduction in
CSF Ab42 is interpreted as heralding an increase in
Ab42 deposition.23,24 Thus, an agent designed to prevent
aggregation should elevate Ab42 CSF levels to the nor-
mal range, unless the therapeutic agent acts both to pre-
vent aggregation and to increase clearance or
degradation. Furthermore, there was no effect on CSF
Ab40 levels, yet the preclinical in vitro data had shown
no difference in the binding potential between Ab40 and
Ab42. Tramiprosate had no effects on cognitive and clin-
ical assessments, which is unsurprising given the short
duration of the trial. The biomarker effects on CSF
Ab42 were considered sufficiently interesting to promote
the Alphase phase 3 trial.
TRAMIPROSATE PHASE 3 TRIAL. Alphase was a
double-blind, placebo-controlled multicenter study that
enrolled 1,052 patients in North America and Canada.25
Tramiprosate was administered at 100mg b.i.d. and
150mg b.i.d. for 78 weeks. The primary endpoint meas-
ures were the Alzheimer’s Disease Assessment Scale–Cog-
nitive Subscale (ADAS-cog) and Clinical Dementia
Rating–Sum of Boxes (CDR-SB). The study was pow-
ered to detect a 25% reduction in clinical deterioration.
Hippocampal volume changes were assessed by magnetic
resonance imaging (MRI) and used as a measure of dis-
ease modification. Unfortunately, this trial failed its pri-
mary and secondary endpoints. For unknown reasons,
there was a significant variance introduced at different
clinical trial sites that confounded the prespecified statis-
tical analysis. Post hoc analysis showed some evidence of
reduced hippocampal volume loss. Given that a surpris-
ing feature of the phase 2 data was a reduction in Ab42
in the CSF, it is regrettable that these data are not avail-
able from the Alphase study. Tramiprosate is currently
marketed as an over-the-counter supplement, Vivimind,
for memory improvement.
Tarenflurbil (R-Flurbiprofen)
WHAT WAS THE HYPOTHESIS BEING TESTED?. Epi-
demiological data suggest that the use of nonsteroidal
anti-inflammatory drugs (NSAIDs) may offer some pro-
tection against the onset of AD,26 especially longer-term
use,27,28 although this has not been seen by others.29–31
Interventional studies have been negative.32
However, anti-inflammatory agents were tested for
their ability to affect Ab production,33 and remarkably
several commonly prescribed NSAIDs reduced Ab42.
Sulindac, indomethacin, and ibuprofen reduced the pro-
duction of Ab42, and this suppression was compensated
for by an increase in the shorter Ab metabolites, espe-
cially Ab38. This work opened a new field of pharmaco-
logical intervention: the c-secretase modulators. These
agents are not inhibitors of c-secretase, but shift the
cleavage sites in favor of the production of shorter forms
of Ab. Most importantly, they do not affect the process-
ing of an important substrate of c-secretase, Notch.34
The effects on Ab42 production were not mediated via
inhibition of the NSAIDs’ primary pharmacological tar-
get, the cyclooxygenase (COX) enzymes COX1 and
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COX2. It was shown that flurbiprofen racemate and the
S- and R- enantiomers were equipotent,35 allowing use
of R-flurbiprofen enantiomer (a less active COX inhibi-
tor), thus reducing unwanted side effects, especially gas-
trointestinal toxicity. The hypothesis being tested was
that R-flurbiprofen, subsequently named tarenflurbil,
would provide a disease-modifying therapeutic agent for
AD by reducing the production of Ab42 in the brains of
AD patients.
DID THE PRECLINICAL DATA OFFER SUPPORT FOR
THE HYPOTHESIS?. The original published work on
tarenflurbil35 did not establish full in vitro dose responses
for inhibition of Ab42 production. Other workers have
used photoaffinity ligands attached to tarenflurbil and
demonstrated that these were able to bind to an APP-
derived substrate, but not to components of c-secretase
itself.36 However, subsequent studies have shown that tar-
enflurbil most likely binds allosterically to the c-secretase
complex37–39 that mediates a change in spectrum of Ab
metabolites in favor of shorter species39–41 with a median
effective concentration (EC50) of Ab42 inhibition of
250lM. Although the rationale of using tarenflurbil to
reduce the potential side effect liability of COX inhibi-
tion has been widely accepted, it remains a more potent
COX1 inhibitor (IC505 44lM) than an inhibitor of
Ab42 production.42 Thus, doses of tarenflurbil that sup-
pressed Ab42 production would always have COX1 sup-
pression as a potential liability, or as an additional
mechanism of efficacy, depending on the context.
The first publication of in vivo pharmacology was
not comprehensive; 3 doses (10, 25, and 50mg/kg) of
tarenflurbil were administered for 3 days to Tg2576
mice with levels of brain Ab42 and Ab40 measured.35
All 3 doses showed a reduction, but there was no dose
response and the group sizes were low, ranging from 4 to
7 mice per group. The brain and plasma levels of taren-
flurbil also did not increase in a dose-proportional man-
ner. The measured brain levels of tarenflurbil were
between 1.5 and 2.6lM, some 100-fold lower than the
in vitro EC50 concentration. This discrepancy makes the
suppression of Ab42 levels difficult to interpret. A
follow-up study in TG2576 mice looked at a longer-
term dosing "preventative" paradigm (Fig 1), where 2
parallel groups were dosed at 10mg/kg tarenflurbil for 4
months between the ages of 8–9 and 11.5–12 months.43
Another group was dosed for 2 weeks from 17.5–18 to
18–19 months. The brains of the mice were analyzed
using enzyme-linked immunosorbent assays (ELISAs) for
Ab40 and Ab42 levels after formic acid and detergent
extraction. Plaque burden was measured using immuno-
histochemistry. None of the treatment paradigms reduced
FIGURE 1: (A) The time course of the development of amy-
loid plaque in a typical APP transgenic mouse model. (B) Pre-
ventative paradigm. A potential amyloidocentric therapeutic
agent is administered with dosing starting prior to the onset
of amyloidosis. The therapeutic acts to delay the initial amy-
loid seeding events in a concentration-dependent manner but
does not affect the rate of amyloid deposition. (C) Therapeu-
tic paradigm. A potential amyloidocentric therapeutic agent is
administered with dosing starting after the onset of amyloi-
dosis. The therapeutic agent acts to slow the rate of amyloid
deposition in a concentration-dependent manner. The dose
responses of the therapeutic agent are very similar in B and
C, but are potentially mediated via different mechanisms, and
their construct validity in regard to the clinical situation has
to be carefully considered.
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Ab42 or Ab40. Surprisingly, plaque burden was reduced
in the therapeutic paradigm but not the preventative par-
adigm. The discrepancy between a lack of effect on
quantitative measurements of Ab42 and Ab40, and a sig-
nificant lowering of plaque burden in the group that
received just 2 weeks of tarenflurbil versus 4 months
administration in the preventative group, makes these
experiments difficult to interpret. Brain analysis of taren-
flurbil and S-flurbiprofen showed evidence of significant
enantiomeric biotransformation, and the total flurbipro-
fen concentration was 1lM, about 250-fold lower than
the in vitro EC50. Other workers delivered tarenflurbil in
food to 4- to 5-month-old Tg2576 mice at an average
dose of 32mg/kg/day for 9 days.41 The study duration
was cut short due to toxicity, which reduced the group
size to N5 5. The tarenflurbil brain concentration was
1.3lM. There was a reduction in brain Ab40, but not
Ab42, which increased compared to the control group.
Given the very low N, and evidence of toxicity, interpre-
tation of this study is challenging. Another study exam-
ined Ab42 and Ab40 levels in the cortex and
hippocampus of 7- to 8-month-old Tg2576 mice follow-
ing extraction with guanidinium HCl.44 The mice
received 25, 50, and 100mg/kg flurbiprofen for 3 days.
There were no effects on Ab42 and Ab40. A second
experiment at lower doses of 10 and 25mg/kg showed a
significant reduction in Ab40 in the cortex but not in
the hippocampus; Ab42 was unaffected in both brain
regions at both doses. Finally, another group adminis-
tered 25mg/kg/day to 7- to 8-month-old Tg2576 mice
for 7 days. There was no inhibition of brain Ab42 or
Ab40 levels extracted using guanidinium HCl.42
In summary, the preclinical science identified a new
pharmacological approach to the suppression of Ab42
production. The in vitro data provided evidence for sup-
pression of Ab42 from cells with an EC50 of 250lM,
although a clear modulator effect—a suppression of
Ab42 coupled to an increase in shorter forms of Ab—
was not always demonstrated. The in vitro EC50 concen-
tration of tarenflurbil was never approached in the brain
in the in vivo experiments due to the lack of brain pene-
tration (about 1.5% of plasma levels42) and dose-limiting
toxicity. A dose response of Ab42 suppression, coupled
to brain drug levels that were consistent with the EC50,
was not demonstrated.
PRECLINICAL TO CLINICAL TRANSLATION. The clinical
development of tarenflurbil appears to have been based
on the few preclinical experiments that showed a reduc-
tion in brain Ab42 levels. In a phase 1 study, 3 cohorts
of 16 healthy aged subjects received either 400, 800, or
1600mg/day (n5 12, administered in 2 doses) or pla-
cebo (n5 4) for 21 days.45 The drug was well tolerated
at all doses, and there was a dose-proportional increase
in tarenflurbil concentrations in the CSF. At the highest
dose, 800mg b.i.d., the mean tarenflurbil concentration
in the CSF was 1.2lM, some 200-fold below its EC50
concentration for the inhibition of Ab42 production in
cell culture. There was no lowering of Ab42 levels in the
CSF at any dose.
DID THE CLINICAL PROGRAM ESTABLISH THAT THE
DRUG WAS MEDIATING THE DESIRED EFFECT, AND
HOW ROBUST WERE THE PHASE 2 DATA THAT
WERE USED TO PROGRESS TO A PHASE 3
TRIAL?. The phase 2 clinical trial studied 210 mild–
moderate AD patients with MMSE scores between 15
and 26.46 Patients received either tarenflurbil 400mg
b.i.d. (n5 69), 800mg b.i.d. (n5 70), or placebo
(n5 71) for 12 months in a multicenter, placebo-
controlled double-blind study. The primary outcome
measures were ADAS-cog and 1 functional assessment,
either the Alzheimer’s Disease Cooperative Study–Activ-
ities of Daily Living Inventory (ADCS-ADL) or the
CDR-SB. An analysis showed an apparent interaction
between the baseline cognitive and functional scores and
treatment effect, so that efficacy analyses were performed
separately for the mild (MMSE> 20) and moderate AD
patients. When the analyses were performed in this way,
800mg b.i.d. tarenflurbil-treated patients showed a signif-
icantly slower rate of decline of ADCS-ADL; ADAS-cog
and CDR-SB showed similar effect sizes but were not
statistically significant. In the moderate AD group
(MMSE 19), the placebo group demonstrated a signifi-
cantly lower rate of decline in all 3 outcome measures
than did the 800mg b.i.d. tarenflurbil group. These
somewhat paradoxical findings are difficult to interpret.
However, the change in ADCS-ADL over the 12-month
period was higher in the mild AD placebo group than
the moderate AD placebo group, whereas for the 2 other
primary outcome measures, ADAS-cog and CDR-SB,
the moderate AD group showed greater deterioration, as
might be expected. Thus, the effect seen at 800mg b.i.d.
tarenflurbil in mild AD patients might have been due to
an unusually large placebo group deterioration rather
than a bona fide treatment effect. Importantly, proof of
mechanism—a change in the spectrum of Ab metabolites
in the CSF in favor of shorter forms—was not assessed.
TARENFLURBIL PHASE 3 TRIAL. The phase 3 study
enrolled 1,646 mild AD patients in a multisite, random-
ized, double-blind placebo-controlled trial comparing
800mg b.i.d. tarenflurbil versus placebo for 18 months.47
The primary outcome measures were change at 18
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months from baseline on ADAS-cog and ADCS-ADL.
There was no difference between the drug-treated and
placebo-treated groups on the primary outcome meas-
ures, and CSF analyses of Ab metabolite spectrum were
not performed.
Semagacestat
WHAT WAS THE HYPOTHESIS BEING TESTED?. c-Sec-
retase activity is required to release the Ab peptide,48,49
hence inhibitors of c-secretase should reduce Ab produc-
tion. In the simplest interpretation of the amyloid hypoth-
esis, which posits that continued deposition of Ab drives
pathological processes resulting in neuronal dysfunction
and death, a c-secretase inhibitor (GSI) that reduced Ab
production would slow the progression of AD. Semagace-
stat is a "classical" GSI,50 acting as a noncompetitive
enzyme inhibitor with an allosteric binding site.
DID THE PRECLINICAL DATA OFFER SUPPORT FOR
THE HYPOTHESIS?. c-Secretase is responsible for the
final cleavage of the APP C-terminal domain following
cleavage by either a- or b-secretase and also cleaves a wide
range of substrates, including Notch.51,52 The Notch sig-
naling pathway is critical for cell fate determination in
many dividing cells and is therefore a significant potential
safety liability for a GSI. Several drug discovery programs
have sought compounds that were selective for Ab versus
Notch inhibition so as to provide a margin of safety.53–55
However, the in vitro assays (cell-free and cell-based)
employed, although they do allow compounds to be com-
pared with each other, are of unknown predictive validity
for the in vivo situation. Semagacestat inhibited Ab pro-
duction with EC505 14.9nM in HEK293 cells stably
transfected with hAPPSwe cDNA.56 In HEK293 cells sta-
bly transfected with the Notch dE cDNA construct, sema-
gacestat inhibited the production of the Notch
intracellular domain with EC505 46nM (P. C. May, per-
sonal communication). This indicated that semagacestat
has a cell-based Ab inhibition/Notch inhibition ratio of
3. The dose-related inhibition of Ab production in cell-
based assays has been widely replicated but with slightly
different potencies and consequently different Ab/Notch
inhibition ratios: for example, 1.3,57 0.8,55 and 20.5.58
The most informative study was performed using a cell-
free, quantitative c-secretase in vitro assay where Notch
and APP substrate concentrations were accurately con-
trolled.59 This demonstrated an Ab/Notch ratio of 0.1.
These data suggest that for semagacestat, the separation of
inhibition of Ab production over Notch inhibition was
marginal.
Preclinical in vitro and in vivo studies revealed that
the pharmacology of semagacestat and of GSIs in general
was complex. This led to a biphasic stimulation/inhibition
of Ab production determined by both substrate availability
and compound concentration.58,60,61 The mechanistic
explanation for this effect remains obscure. In vivo experi-
ments demonstrated a similar stimulation/inhibition effect
of semagacestat on plasma Ab levels, but this was not dem-
onstrated in mouse brain,62 guinea pig brain,61 or rat
brain.58 Semagacestat was also orally administered at 2mg/
kg acutely to beagle dogs to assess the pharmacokinetic
and pharmacodynamic profile in plasma and in CSF.63
This study showed that Ab40 and Ab42 peptides were
lowered in the CSF by up to 60% and that suppression of
Ab production was sustained for longer in the CSF than in
the plasma compartment. With lower doses of semagace-
stat, or at longer time-points at which point compound
concentrations are declining, there was an elevation of Ab
in plasma that was not seen in the CSF.64 These data can
be rationalized as follows. At low GSI and substrate con-
centrations, c-secretase is stimulated. APP expression in
peripheral tissues is lower than in the brain, hence periph-
erally derived Ab is initially suppressed following an oral
dose (when compound levels are high), but then stimu-
lated as compound levels diminish. In the brain, where
APP expression is higher, the stimulation of Ab is less
apparent. As Ab is trafficked out of the brain rapidly,65 it
might also be technically challenging to detect GSI-
induced increases in Ab levels.
In PDAPP transgenic mice, which overexpress the
hAPP717 mutation,66 dose-related inhibition of brain
Ab production was demonstrated after acute and 7-day
dosing.67 In a chronic study, semagacestat was adminis-
tered daily to 5-month-old PDAPP mice for 5 months at
3, 10, and 30mg/kg.68 This resulted in dose-related
reduction in insoluble brain Ab that was significantly dif-
ferent from control groups at the highest dose for both
Ab40 and Ab42. There was no significant reduction in
plaque as measured immunohistochemically. Interestingly,
semagacestat was a more potent inhibitor of Ab40 than
Ab42 production, an effect seen by others using semaga-
cestat61 and other GSIs of this class.69 Importantly, the
dosing of semagacestat was initiated prior to the onset of
Ab plaque deposition in the PDAPP mice, and thus
reflects a preventative rather than a therapeutic dosing
paradigm. This is an important concept from 2 perspec-
tives: first, in how it relates to its proposed clinical use;
and second, because a therapeutic agent can inhibit Ab
deposition via fundamentally different mechanisms (see
Fig 1). Several studies have investigated this issue and
demonstrated that GSIs prevent the formation of new
Ab plaques, but even with significant suppression of Ab
production, do not mediate the clearance of existing pla-
ques.69–72
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Preclinical to Clinical Translation
In healthy volunteers, semagacestat has a time to reach
maximum concentration in plasma of 1 to 1.5 hours and a
plasma half-life of 2.5 hours when administered daily for
14 days at doses ranging from 5 to 50mg/person. There
was a dose-related reduction in plasma Ab, followed by a
stimulation of up to 500% over baseline for the lowest
dose of semagacestat.73 In this study, no reduction in CSF
Ab could be detected when sampled 6 hours after com-
pound dosing. In a phase 2 study, semagacestat was given
at 30mg every day (q.d.) for 1 week followed by 40 mg
q.d. for 5 weeks to 33 mild–moderate AD patients.74 At
the end of the study, there was evidence of Notch-related
effects on lymphocytes, but on the whole the drug was
well tolerated. There was a 38% suppression of plasma
Ab40 but no effect on CSF Ab40/42.
In the preclinical studies in the PDAPP mouse,
30mg/kg given once daily for 5 months reduced deposited
Ab and suppressed plasma Ab by approximately 60% at
maximal drug concentration. Thus, this level of plasma Ab
reduction was sought in human studies as a translational
biomarker. Accordingly, a phase 1 study investigated the
Ab pharmacodynamic effect of 3 doses of semagacestat:
60, 100, or 140mg in normal humans.75 Blood samples
were taken at regular intervals up to 24 hours postdose for
analysis of compound, and Ab concentration and CSF
samples were collected 4 hours after dosing. The maxi-
mum percentage decrease in plasma Ab from baseline val-
ues was 50% for the 60mg group and 73% for the 140mg
dose, and occurred between 4 and 6 hours postdose,
returning to baseline values between 8 and 13 hours later,
depending on the dose. There were slight reductions in
CSF Ab that were significant for Ab40 at the 140mg dose.
As seen previously, there was a large increase in plasma Ab
that followed the initial suppression phase.
Although the plasma biomarker response confirmed
that c-secretase was being inhibited in a dose-related man-
ner, there was no evidence that the production of brain Ab
was being affected. Given the excellent brain penetrant
properties of semagacestat, it was unlikely that brain c-
secretase was unaffected by the compound, and the most
likely explanation for the lack of a measurable Ab response
lay in the technical challenge of measuring CSF Ab.
DID THE CLINICAL PROGRAM ESTABLISH THAT THE
DRUG WAS MEDIATING THE DESIRED EFFECT, AND
HOW ROBUST WERE THE PHASE 2 DATA THAT
WERE USED TO PROGRESS TO A PHASE 3
TRIAL?. The inhibition of brain Ab production by sema-
gacestat was measured using the stable isotope kinetic
effect assay.65 Humans were given a continuous intrave-
nous (i.v.) infusion of 13C-leucine for 9 hours to isotope-
label proteins. CSF was collected via a spinal tap every
hour for up to 36 hours, and Ab species were immunopre-
cipitated using a mid-domain antibody before mass spec-
trometry analysis. The fractional incorporation of 13C-
leucine was used to analyze the rate of production and
clearance of Ab. Semagacestat was administered in a single
oral dose of 100, 140, and 280mg, and the effects on brain
Ab synthesis and clearance were measured.76 This crucial
study proved that semagacestat was able to inhibit brain
Ab production by 47%, 52%, and 84% at 100, 140, and
280mg doses, respectively, over a 12-hour period.
A phase 2 safety study77 investigated the tolerability
of 100 and 140mg once daily dosing over a 12-week
period in mild–moderate AD patients. Although the
drug was well tolerated overall, there was an increased
incidence of skin rashes and hair color changes, which
were indicative of inhibition of Notch signaling. In retro-
spect, it is noteworthy that both doses numerically wors-
ened ADAS-cog scores. Plasma Ab levels were inhibited
by 65% at the 140mg dose.
It is apparent that semagacestat was cautiously
developed, and that given the side effect profile of Notch
inhibition, it was not possible to increase the dose above
140mg q.d. to garner increased efficacy.
SEMAGACESTAT PHASE 3 TRIALS. Two phase 3 trials
(Identity 1 and Identity 2, ClinicalTrials.gov identifiers
NCT00594568 and NTC0076241122600) planned to
enroll 2,600 mild–moderate AD patients who were
randomized to placebo, 100mg semagacestat, and 140mg
semagacestat once daily for 76 weeks in 2 trials. The
ADAS-cog and ADCS-ADL were the coprimary outcome
measures. These trials were halted after an interim futility
analysis of Identity 1 showed a significantly increased inci-
dence of skin cancer, infections, and white blood cell and
other hematologic abnormalities.78 There was no improve-
ment in cognition as measured by the ADAS-cog, and
activities of daily living were significantly worsened at the
highest dose. The 140mg dose showed a significant wor-
sening of the CDR-SB and the MMSE. CSF levels of
Ab40, Ab42, and tau were not altered by semagacestat
treatment, whereas phospho-tau 181 (ptau) was signifi-
cantly, but modestly, reduced. There were no drug effects
on fluorodeoxyglucose positron emission tomography
(PET), 18F-florbetapir PET to measure deposited brain
Ab, or volumetric MRI. At the end of a 32-week safety
extension phase, after cessation of dosing, there was no dif-
ference in the changes from baseline in the coprimary
measures across the 3 groups; other abnormalities in
immune and renal function had not fully resolved.
It is likely, given that c-secretase has many sub-
strates, that the deleterious effects mediated by
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semagacestat are unrelated to Ab metabolism but will
never be elucidated.
Bapineuzumab
WHAT WAS THE HYPOTHESIS BEING TESTED?. The
hypothesis being tested was that administration of an
antibody directed at the N-terminus of Ab would medi-
ate the clearance of Ab plaque from the brain paren-
chyma of AD patients and thereby reduce the
progression of cognitive decline and deterioration of
activities of daily living in AD.
DID THE PRECLINICAL DATA OFFER SUPPORT FOR
THE HYPOTHESIS?. The development of bapineuzu-
mab stems from a groundbreaking study showing that
immunization of PDAPP transgenic mice with Ab42
peptide was able to prevent the deposition of Ab plaque
in the brain parenchyma.79 This seminal work opened
up the potential for using antibodies as therapeutic
agents for AD, which although considered earlier80 had
been largely discounted owing to their poor blood–brain
barrier (BBB) penetration. The original study was fol-
lowed by others that confirmed the general principle that
immunization with Ab42 was able to produce anti-Ab
antibodies that acted to prevent Ab plaque deposi-
tion.81,82 The immunization protocol effectively pre-
vented the brain accumulation of insoluble Ab when
antibodies were raised prior to the period of Ab deposi-
tion. This work led to the clinical development of
AN1792, an active immunization using Ab42 peptide as
the immunogen. AN1792 was halted during its phase 2
study due to an unacceptable incidence (6%) of menin-
goencephalitis,83 likely due to the addition of polysorbate
80 to the immunization formulation that resulted in an
inflammatory Th1-cell–mediated response.84 Several
studies have investigated the consequences of Ab vaccina-
tion in some patients that have since died, and their
brains have been made available for postmortem neuro-
pathology. These publications have been informative, but
caution must be exercised, because the group sizes are
low, the appropriate controls (patients receiving placebo)
have not been available, and certain findings that were
statistically significant failed to replicate when the cohort
studied was enlarged.85,86 Also, the same patients are
analyzed in multiple publications.87 Several studies
revealed that AN1792 immunization appeared to reduce
parenchymal Ab plaque but without affecting tau pathol-
ogy88–92 (total number of immunized patients5 13).
Other authors have reported that tau pathology was
modestly reduced and that neurite morphology was nor-
malized in Ab-immunized patients87 (number of immu-
nized patients5 5). Also, 1 study demonstrated that
whereas parenchymal plaque was reduced, total soluble
amyloid levels were increased in gray and white matter93
(number of immunized patients5 2). In terms of the
inflammatory status of the brain, it was surprisingly
shown that overall microglial activation was lowered in
AN1792-immunized patients86 (number of immunized
patients5 11). In summary, these tantalizing studies offer
some evidence (albeit without appropriate controls) for
antibody-mediated resolution of deposited Ab, and rein-
force the value of having brain donation as an important
component of AD clinical trials. The AN1792 antibody
response was predominantly to the free N-terminus of
Ab94; hence, this epitope was targeted with a passive
immunization approach. Bapineuzumab is the humanized
version of 3D6, a highly specific mouse monoclonal anti-
body raised to the Ab amino acid residues 1–5.95 3D6 is
a mouse IgG2b antibody with an affinity for soluble Ab
of <30nM96 and between 3 and 5nM.97 The dissocia-
tion constant (Kd) of the bapineuzumab Fab fragment
for Ab1–40 was recently reported to be 89nM.98 When
11.5-month-old PDAPP mice were treated with weekly
injections of 3D6 for 6 months, the Ab burden (percent-
age of a brain section of the frontal cortex that can be
immunohistochemically stained for Ab) was reduced by
86%.96 However, it is unclear whether this regime
reduced Ab levels to below those present at the start of
dosing, Ab was not quantitated using biochemical assays,
and the potency of 3D6 cannot be calculated, because
the dose administered was not reported. In a second
study, 3D6 was administered (dose not reported) to 13-
month-old PDAPP mice for either 3 or 35 days. In this
experiment, although there was some semiquantitative
evidence for a reduction in small and diffuse plaques,
there was no quantitative data on insoluble Ab levels,
and so the overall efficacy of the treatment is unknown.
The mechanism by which anti-Ab antibodies clear brain
Ab was investigated using an ex vivo assay in which 3D6
or 3D6 Fab fragments were administered together with
mouse microglia cells onto nonfixed brain slices taken
from either AD brains or PDAPP mouse brains. In this
assay system, the immunohistochemical analysis suggested
that Fc-mediated microglial phagocytosis was a likely
mechanism by which Ab plaques could be removed from
the brain. Thus, the therapeutic hypothesis was that pas-
sive immunization with bapineuzumab would remove Ab
plaques from the brains of AD patients, most probably via
stimulation of microglial activation, but also potentially
via direct mechanical disruption of Ab plaque mediated
by antibody binding99 and the direct inhibition of Ab
fibrillogenesis.100 An in vivo study that involved the direct
application of antibody to the brain via a cranial window
provided evidence that both intact and Fab fragments of
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3D6 were able to mediate resolution of plaque in a 3-day
time period as measured by multiphoton imaging.99 The
translatability of this work to systemic dosing is challeng-
ing, because there was evidence that the opening of the
skull caused an inflammatory response, and the concentra-
tions of antibodies administered were not reported. The
preclinical data therefore supported the concept that pas-
sive immunization of bapineuzumab in AD patients would
result in a slowing of Ab deposition, but there were no
quantitative data to support a reduction of Ab plaque
below that present at the start of dosing. A study was per-
formed to establish target engagement that entailed sys-
temic injection of trace amounts of 125I-3D6 into PDAPP
transgenic mice at various ages.101 Radioactivity was
higher in the hippocampus than in the cerebellum, and
radioactivity in the hippocampus increased from day 7 to
day 14 after 125I-3D6 injection. Surprisingly, there was
very little difference in binding between the cortex and
the cerebellum, although it is known that the cortex devel-
ops Ab plaques in the PDAPP model whereas the cerebel-
lum does not.95 In a competition experiment, up to
30mg/kg of unlabeled 3D6 was unable to compete with
up to 170ng/mouse of 125I-3D6 binding that was meas-
ured in cerebellum, hippocampus, or cortex. Although this
could mean that antibody binding sites on deposited Ab
could not be saturated, this protocol is similar to a classic
competition experiment that is used to determine specific
from nonspecific binding. Therefore, a different interpreta-
tion is that a significant proportion of the 125I-3D6 bind-
ing is nonspecific. In a different study,97 it was
demonstrated in 24- to 29-month-old PDAPP mice that
40mg/kg of biotinylated 3D6 was unable to bind to
deposited Ab plaque. The authors concluded that the anti-
body is bound by soluble Ab that might be present in
increased concentration around plaques as a consequence
of insoluble-to-soluble phase Ab exchange. If this is true,
then 3D6 would be unable to access deposited plaque to
mediate microglial-mediated Ab clearance.
In another study, 50mg/kg intraperitoneally (i.p.)
per week of 3D6 administered for 6 weeks resulted in a
significant increase in the severity and incidence of
microhemorrhage.102 In a later study, using younger 12-
month-old mice and much lower doses of 3D6 (loading
dose of 7.5mg/kg, followed by maintenance dose of
3mg/kg; loading dose of 0.75mg/kg, followed by mainte-
nance dose of 0.3mg/kg; loading dose of 0.25mg/kg, fol-
lowed by maintenance dose of 0.1mg/kg; treatments
administered weekly for 6 months), it was demonstrated
that although 3D6 increased the incidence of microhe-
morrhage, this could be ameliorated at lower doses.103 In
addition, it was demonstrated that 3D6 treatment
removed vascular amyloid and potentially prevented dep-
osition. At the start of the study, the incidence of vascu-
lar amyloid deposits in PDAPP mice was 40%, thus it
is not possible to differentiate between the effects of 3D6
to prevent vascular amyloid deposition as opposed to
3D6 clearing existing vascular amyloid.
PRECLINICAL TO CLINICAL TRANSLATION. To date,
2 preclinical studies have been published where the dose
of 3D6 is reported and where a reduction in plaque dep-
osition was found. Seubert et al performed 3 studies in
PDAPP transgenic mice.104 In a preventative study, 3D6
(IgG2a) was administered i.p. at 10mg/kg/wk to 4-
month-old PDAPP mice for 12 months. 3D6 treatment
dramatically reduced deposited Ab total accrual by 89%
measured using specific Ab ELISAs. When 3D6 was
administered in a therapeutic study to 12-month-old
mice at 3mg/kg/wk for 6 months, there was a 93%
reduction in immunohistochemical staining compared to
controls. Ab was not quantitated biochemically for this
study, but in a second identical study Ab total accrual
was reduced by 77% and plaque load by 98%. In these
studies, it is not possible to confirm whether 3D6
reduced Ab deposition below predosing levels. Also,
although a preclinical study can be readily established to
be preventative because there is no deposited Ab present
at the start of the study, judging whether a study is thera-
peutic and moreover translatable to human disease is
much more challenging, because it requires an assessment
of how the deposited Ab levels in the model system
relate to the human disease. This point was investigated
by Demattos et al97 in a series of experiments with 3D6
(IgG2b). At 5.5 months of age, PDAPP mice have not
begun to deposit Ab in brain parenchyma. 3D6 was
administered to 5.5-month-old PDAPP mice for 7
months at a dose of 12.5mg/kg s.c. once weekly. This
dosing regimen produced a highly significant 68% reduc-
tion in deposited Ab42 accrual in the hippocampus.
When administered at 12.5mg/kg once weekly s.c. for 3
months to PDAPP mice at a starting age of 9 months,
although 3D6 was again able to reduce deposited Ab42
statistically significantly compared to the control group,
the treatment failed to reduce the levels of Ab to below
the levels present at the start of the study. When 3D6
was administered to mice at 18 months or 23.5 months
of age, 3D6 failed to inhibit deposited Ab42 when com-
pared to the control group. At these 2 time periods, Ab
accrual in control animals has reached a plateau, and in
this respect resembles AD. However, in the latter study it
was demonstrated that 3D6 mediated a significant
increase in microhemorrhage despite the lack of efficacy
on parenchymal plaque removal. In summary, the pre-
clinical data support a profile where 3D6 is robustly
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efficacious in a preventative rather than in a therapeutic
dosing paradigm. However, one must be cautious in
extrapolating from a transgenic model that has rapid Ab
deposition to man, where Ab deposition takes place over
many years.
DID THE CLINICAL PROGRAM ESTABLISH THAT
THE DRUG WAS MEDIATING THE DESIRED
EFFECT, AND HOW ROBUST WERE THE PHASE 2
DATA THAT WERE USED TO PROGRESS TO A PHASE
3 TRIAL?. Bapineuzumab is the humanized IgG1 ver-
sion of 3D6. In the phase 2 multiple ascending single-
dose study, 0.5, 1.5, and 5.0mg/kg bapineuzumab were
given to mild–moderate AD patients via i.v. infusion.105
This established the mean half-life of bapineuzumab to
be 23.7 days. Vasogenic edema (now referred to as
amyloid-related imaging abnormality–edema [ARIA-E])
was identified in 3 of 10 patients receiving the 5mg/kg
dose, with 1 of these patients exhibiting microhemor-
rhage (now referred to as ARIA-M). Based on these data,
a phase 2 study enrolled 234 mild–moderate AD patients
who were assigned to receive 0.15, 0.5, 1.0, or 2.0mg/kg
bapineuzumab, or a placebo given by i.v. infusion every
13 weeks for 78 weeks.106 This was powered as a safety
study, but the coprimary efficacy endpoints were the
ADAS-cog and Disability Assessment for Dementia
(DAD). Other study assessments included the Neuropsy-
chological Test Battery, CDR-SB, and exploratory CSF
and imaging biomarkers. There were no significant dif-
ferences in the ADAS-cog and DAD between placebo
and any of the bapineuzumab dose groups. An explora-
tory analysis was conducted on those patients who had
received all 6 bapineuzumab infusions. When all bapi-
neuzumab dose cohorts were pooled, there was a signifi-
cant difference at week 78 between bapineuzumab-
treated patients and placebo on the ADAS-cog and DAD
measurements. The incidence of ARIA-E increased with
increasing bapineuzumab dose, with the highest 2.0mg/
kg dose resulting in a 27% incidence. ARIA-E also
increased with APOE4 gene dosage, with 2 copies of the
gene resulting in a 33.3% incidence in bapineuzumab-
treated patients. There were no episodes of ARIA-E in
the placebo group. Using an identical dosing regimen in
mild–moderate AD patients, the effects of bapineuzumab
on 11C-Pittsburgh compound B (PiB) PET imaging were
investigated.107 Patients were given 11C-PiB PET scans at
baseline and then at weeks 20, 45, and 78. In
bapineuzumab-treated patients, there was an 8.5%
decrease in PiB retention compared with a 16.9%
increase in the placebo group, and this difference was
statistically significant. The number of patients in this
trial was low (7 in the placebo group and 19 in the
bapineuzumab-treated group), but nevertheless this find-
ing was consistent with the proposed mechanism of
action. CSF samples were taken from some of the
patients in these 2 phase 2 trials, and Abx–42, Ab1–42,
total tau, and ptau were measured. These samples were
pooled to give 27 bapineuzumab and 19 placebo sam-
ples, and revealed that there was a significant reduction
in ptau, but no effect on the other metabolites,108 an
effect consistent with a reduction in disease-related neu-
ronal loss or damage.
These phase 2 data provided some evidence that
bapineuzumab treatment may be disease modifying.
There were data suggesting a reduction in amyloid pla-
que and a decrease in CSF ptau, and there was some evi-
dence of cognitive benefit. It was also clear that ARIA-E
and ARIA-M were significant treatment adverse events
that were more common in APOE4 gene carriers.
BAPINEUZUMAB PHASE 3 TRIAL. Four phase 3 trials
were launched involving a total of 4,570 mild–moderate
AD patients randomized to placebo and bapineuzu-
mab.109 Two separate trials were conducted in APOE4
carriers and noncarriers predominantly in North America
(ClinicalTrials.gov identifiers NCT00575055 and
NCT00574132); 2 parallel trials were conducted pre-
dominantly in the rest of the world (NCT00667810 and
NCT00676143). Bapineuzumab was administered to
patients who were APOE4 carriers at 0.5mg/kg and in
APOE4 noncarriers at 0.5mg/kg, 1mg/kg, and 2mg/kg
initially, with the 2mg/kg dose being abandoned due to
ARIA-E and ARIA-M. Bapineuzumab failed to meet the
primary outcome measures on ADAS-cog and DAD in
trials NCT00575055 and NCT00574132. Consequently,
trials NCT00667810 and NCT00676143 were termi-
nated. Of note, although the group sizes were low, there
was some evidence in APOE4 carriers of a modest reduc-
tion in PiB PET binding when compared with the pla-
cebo group, although in contrast to the phase 2 study,
there was no difference when compared with the baseline
values. There was also a statistically significant although
modest reduction in ptau in both the APOE4 carriers
and noncarriers. On pooled data from trials
NCT00575055 and NCT00574132, there was a signifi-
cant but modest dose-related increase in brain atrophy
due to bapineuzumab therapy. As was seen in the phase
2 studies, there was a dose-related increase in ARIA-E
with bapineuzumab therapy that was more prevalent in
APOE4 carriers (21% at the 0.5mg/kg dose, and 6% and
13% at the 0.5mg/kg and 1.0mg/kg doses, respectively)
than in APOE4 noncarriers. Given the lack of clinical
benefit, the biological significance of these biomarker
changes is difficult to interpret.
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Solanezumab
WHAT WAS THE HYPOTHESIS BEING TESTED?. Sola-
nezumab is a humanized IgG1 antibody derived from
the mouse monoclonal antibody m266. The m266
monoclonal antibody was raised to a peptide-conjugate
containing Ab13–28.110 The antibody m266 recognizes
an epitope in the Ab16–24 midregion111 with low pico-
molar affinity.112 Solanezumab recognizes soluble, mono-
meric Ab, but not deposited Ab or amyloid
plaques.102,112 In in vitro studies, m266 was able to
deplete solutions of Ab mixed with APOE, bovine serum
albumin, or mouse IgG when separated by a 25kDa cut-
off dialysis membrane, effectively acting as an Ab
"sink."112 Further experiments in PDAPP transgenic
mice demonstrated that m266 was able to capture Ab40
and Ab42 in the plasma, such that a 0.5mg i.v. treatment
with m266 resulted in the total capture of plasma Ab. If
human Ab was injected into the cisterna magna of non-
transgenic mice, then this could be subsequently detected
bound to m266 in mice pretreated with the antibody,
thus demonstrating the ability of m266 to capture Ab
effluxed from the central nervous system (CNS). In fur-
ther experiments, it was demonstrated that although CSF
and peripheral concentrations of Ab were positively cor-
related in PDAPP mice lacking deposited Ab, this corre-
lation was lost when deposited Ab was present in the
brain.113 However, when 0.5mg m266 was administered
i.v. to PDAPP mice, a positive correlation was demon-
strated between hippocampal amyloid and the total
amount of plasma Ab measured at 24 hours. This result
established that peripherally administered m266 was able
to sequester Ab and act as a peripheral sink for Ab
effluxed from the brain. Thus, the hypothesis for solane-
zumab treatment was that by administering the human-
ized version of m266 to AD patients, the net efflux of
Ab from the brains of AD patients would be augmented,
leading ultimately to resolution or a decrease of depos-
ited Ab. This hypothesis rests on the assumption that
deposited Ab and soluble Ab in interstitial CSF are in
equilibrium.
DID THE PRECLINICAL DATA OFFER SUPPORT FOR
THE HYPOTHESIS?. Whereas the data supporting the
peripheral sink effects of m266 are robust, data showing that
m266 treatment will reduce deposited parenchymal Ab were
not compelling. The antibody m266 was administered at
0.5mg/mouse i.p. every 2 weeks for 5 months in 4-month-
old PDAPP mice, likely prior to the deposition of Ab. At 9
months, the number of mice with <50% of the cortex
immunohistochemistry for Ab was reduced in m266-treated
mice. However, insoluble total Ab and Ab42 were not signif-
icantly different from control.112 Furthermore, this experi-
ment represents a preventative rather than a therapeutic
treatment paradigm. Seubert and colleagues administered
m266 at 10 and 3mg/kg/wk i.p. in 2 separate studies.104
Dosing was started at 12 months and continued until 18
months. At the 10mg/kg dose, m266 failed to reduce depos-
ited Ab as measured using immunohistochemistry; there was
a trend for increased amyloidosis. At the 3mg/kg dose,
m266 failed to show efficacy as measured either by Ab
immunohistochemistry or by quantitative ELISA of total
brain Ab. In a preventative dosing regimen, where 10mg/kg/
wk m266 was administered from 4 to 16 months of age,
again m266 failed to demonstrate efficacy as assessed either
by Ab immunohistochemistry or quantitative ELISA.
PRECLINICAL TO CLINICAL TRANSLATION. Solane-
zumab, the humanized version of m266, was given to AD
patients in single-dose, dose escalation study in a total of
19 patients.114 The primary outcome measure was to
assess safety, with a secondary outcome being pharmacoki-
netic and pharmacodynamic measurements. Solanezumab
was administered at 0.5, 1.5, 4, and 10mg/kg i.v. in a
saline infusion protocol. All doses were well tolerated,
with no evidence for ARIA-E or ARIA-M. Large increases
in plasma Ab40 and Ab42 were measured in a dose-
related fashion. Although the analyses were not able to
distinguish between free and antibody-bound Ab, the sus-
tained increase in plasma Ab suggests that plasma Ab was
being captured for up to 42 days postdose. Interestingly,
there was a dose-related increase in CSF Ab as well, which
was likely mediated by capture of Ab by the 0.1% of the
peripheral concentration of solanezumab that crossed the
BBB. There were no effects on cognitive measures.
DID THE CLINICAL PROGRAM ESTABLISH THAT
THE DRUG WAS MEDIATING THE DESIRED EFFECT,
AND HOW ROBUST WERE THE PHASE 2 DATA
THAT WERE USED TO PROGRESS TO A PHASE 3
TRIAL?. The phase 2 program studied 52 AD patients
in a placebo-controlled, randomized trial. Several dosing
regimens were compared over a 12-week period: 100mg
solanezumab every 4 weeks, 100mg weekly, 400mg every
4 weeks, 400 mg weekly. The primary outcome measure
was the safety and tolerability of multiple administrations
of solanezumab, with pharmacokinetic and cognitive
assessments as secondary endpoints. There was a rapid,
dose-related and dose regimen–related increase in plasma
Ab40 and Ab42. Treatment-emergent adverse events
were not different between solanezumab-treated patients
and placebo controls. There was no evidence of ARIA-E
or ARIA-M, or of meningoencephalitis, and no treat-
ment effects measureable by ADAS-cog. In this study,
antibody-bound and free Ab40 and Ab42 were assayed
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in CSF samples. These data showed a dose-related and
dose regimen–related increase in total (bound plus
unbound) Ab40 and Ab42 compared to baseline values.
For unbound Ab, there was no treatment effect on
Ab40, but for Ab42 there was a dose-related and dose
regimen–related increase. The increase in total Ab40
(bound and unbound) is most likely due to capture by
solanezumab entering the CNS. The increase in Ab42
(bound and unbound), although somewhat counterintui-
tive, might herald some dissolution of amyloid plaques
that are predominantly comprised of Ab1–42. Thus, the
mechanism of action of solanezumab was demonstrated
in the phase 2 trial with circumstantial evidence of an
effect on Ab plaque.
SOLANEZUMAB PHASE 3 TRIALS. Solanezumab was
tested in 2 randomized, blinded, placebo-controlled
phase 3 trials, Expedition 1 (1,000 mild–moderate AD
patients) and Expedition 2 (1,040 mild–moderate AD
patients; ClinicalTrials.gov identifiers NCT00905372 and
NCT00904683).115 Solanezumab was administered via
i.v. infusion at 400mg per patient every 4 weeks for 80
weeks. The coprimary outcome measures for both trials
were improvement on change from baseline to week 80
in ADAS-cog and ADCS-ADL. Secondary outcome
measures included volumetric MRI, CSF ptau, tau, CSF
Ab, Amyvid PET amyloid imaging, and plasma Ab.
Expedition 1 failed to reach its coprimary outcomes.115
However, in a prespecified secondary analysis in mild
AD patients (MMSE5 20–26), solanezumab signifi-
cantly improved cognitive performance as measured by
ADAS-cog11 and the ADAS-cog14 scale, which is more
sensitive to changes in mild-AD, but failed to demon-
strate an improvement in activities of daily living. As the
data from Expedition 1 were available prior to the termi-
nation of Expedition 2, the primary outcome measures
for Expedition 2 were changed to a single outcome of
improvement in ADAS-cog14 in the mild AD patient
cohort (MMSE5 20–26) measured at 80 weeks. Solane-
zumab failed to meet its primary outcome measure in
Expedition 2. When data from both trials were pooled,
then solanezumab therapy significantly improved cogni-
tive performance as measured by ADAS-cog14, but this
improvement was driven largely from the Expedition 1
result. The pooled data in the mild AD cohort failed to
reveal an improvement in ADCS-ADL, although there
was a positive trend. Of note, in both the bapineuzumab
and solanezumab phase 3 trials, amyloid PET imaging
suggested that approximately 25% of the mild AD
cohort did not have amyloid deposits and thus could not
respond to amyloidocentric therapeutic agents.109,115,116
Solanezumab did not produce significant effects on
deposited amyloid as measured with Amyvid PET amy-
loid imaging agent. As was seen in the phase 2 studies,
there was a significant increase in total (antibody-bound
and free) CSF Ab42 and Ab40 and a reduction in free
CSF Ab40, but no increase in free CSF Ab42. As previ-
ously, there was a very large increase in plasma Ab bound
to antibody. There were no solanezumab-mediated
changes in ptau levels in the CSF and no change in hip-
pocampal or whole brain volume as measured by volu-
metric MRI as a consequence of therapy. However, in
those patients who were treated with solanezumab and
who were amyloid positive as assessed by Amyvid PET,
there was a nonsignificant increase in atrophy.
Based on the data from Expedition 1 and 2, solane-
zumab is currently being tested in Expedition 3, a phase
3 trial in mild AD (ClinicalTrials.gov identifier
NCT01900665) with improvement in ADAS-cog14 and
ADCS-ADL as coprimary endpoints and a positive amy-
loid PET brain scan as an inclusion criterion. The dura-
tion and dosing regimen for Expedition 3 are identical
to those for Expedition 1 and 2.
Intravenous Immunoglobulin G
WHAT WAS THE HYPOTHESIS BEING TESTED?. Intra-
venous immunoglobulin G (IVIg) is a preparation of
pooled polyspecific IgG obtained from the plasma of
large numbers of healthy individuals. IVIg is used to
treat immunodeficiency and inflammatory syndromes. By
using Epstein–Barr virus to immortalize B cells taken
from AD patients,117 it was demonstrated that anti-Ab
antibodies could be detected that recognized the N-
terminus of the Ab peptide but that were also conforma-
tional. It was further demonstrated that about 10-fold
more B-cell lines immortalized from AD patients were
producing anti-Ab antibodies than from controls.118 In
contrast, later studies119 demonstrated that anti-Ab anti-
bodies could be detected in CSF and blood in AD
patients, but at lower titers than in controls. Further
investigations demonstrated that several commercial IVIg
preparations also contained anti-Ab antibodies.120 When
administered to 7 elderly patients with a variety of condi-
tions, but not AD, the treatment reduced total Ab and
Ab42 in CSF by approximately 20%. A retrospective
analysis121 analyzed medical claims for patients >65
years of age from a national database and compared the
incidence of AD over a 5-year period following IVIg.
This revealed a 42% reduction in the risk of being diag-
nosed with AD following IVIg therapy. Together with
the preclinical data79,112 demonstrating several potential
therapeutic modalities for anti-Ab antibodies, it was
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considered worthwhile to test the hypothesis that IVIg
would elicit a therapeutic effect in AD patients.
DID THE PRECLINICAL DATA OFFER SUPPORT FOR
THE HYPOTHESIS?. Given the nature and provenance
of the therapy, there are few published preclinical experi-
ments. Anti-Ab antibodies affinity-purified from IVIg
were shown to inhibit Ab40 and Ab42 fibril forma-
tion.122,123 The same purified preparations were also
shown to inhibit Ab-mediated toxicity in fetal rat pri-
mary hippocampal cells, but the interpretation of direct
Ab-mediated toxicity assays is challenging.9 Other workers
also demonstrated an antiaggregatory effect of affinity-
purified anti-Ab antibodies on Ab-induced toxicity, but
no control antibody was used, and so the specificity of
action is unclear.124 In other experiments, affinity-purified
anti-Ab antibodies at a high concentration of 20lM
increased microglial-mediated Ab clearance in an ex vivo
assay using Ab plaque–laden transgenic mouse brain slices.
In APP23 mice, biodistribution of 111In-labeled affinity-
purified anti-Ab antibodies from IVIg was measured and
compared with rituximab (as a control antibody), and the
anti-Ab mouse monoclonal antibodies 4G8 and 6E10.125
There was no significant difference in the brain binding
between any of the antibodies at time periods up to 4
days, but interpretation is problematic, because it was
unclear whether the APP23 mice used had deposited
parenchymal Ab. IVIg was administered i.p. at a dose of
1g/kg weekly to APP/PS1 transgenic mice with deposited
parenchymal plaque for up to 14 weeks.124 Antihuman
IgG antibodies were used to detect IVIg, and there was
evidence for brain binding, but the experiment did not
reveal specific binding to Ab plaques.
DID THE CLINICAL PROGRAM ESTABLISH THAT THE
DRUG WAS MEDIATING THE DESIRED EFFECT,
AND HOW ROBUST WERE THE PHASE 2 DATA
THAT WERE USED TO PROGRESS TO A PHASE 3
TRIAL?. The development of IVIg was largely driven
from human experimental medicine, and so the normal
evolution of preclinical science to inform human dose
setting and pharmacology was not followed.
The first description of a clinical study with IVIg
was in a 1998–2000 study involving 8 AD patients
treated for 12 months with a monthly dose of IVIg of
0.2g/kg. This study reported a significant improvement
in patients but was never published as a peer-reviewed
paper.126 In another study, 5 AD patients were given
0.4g/kg IVIg every month for 6 months in a non–
placebo-controlled open study.127 Comparing baseline
with measurements taken at the end of the study revealed
a modest reduction in total Ab in CSF, with no change
in free Ab42. There was an increase in total Ab in serum
(2.3-fold), which is marginal compared with the
increases in serum Ab mediated by solanezumab treat-
ment (25,000-fold). The treated patients did not show
a clinical decline over the 6-month period as measured
by ADAS-cog and the MMSE. An open-label dose-rang-
ing study was performed in 8 mild AD patients using an
interrupted dosing design.128 Following a single dose of
0.4g/kg of IVIg, patients were randomly assigned to
0.4g/kg/2 weeks, 0.4g/kg/wk, 1g/kg/2 weeks, or 2g/kg/4
weeks for 6 months of treatment. IVIg was then with-
drawn for 3 months, after which all patients were treated
with 1g IVIg/kg/2 weeks for 3 months followed by 0.4g/
kg/2 weeks for a further 6 months. Given that there were
only 2 patients per dosing arm in this uncontrolled
study, it is difficult to infer very much from the cognitive
measures that were made. However, the data show a
favorable change in MMSE over the first 6 months of
dosing followed by a decline during the 3-month treat-
ment withdrawal period. Data from a single patient on
the highest dose of 2g/kg/4 weeks demonstrated increases
in plasma Ab following each administration, but these
were minor (1.8-fold) compared with that achieved by
solanezumab.
A randomized, phase 2 dose-finding trial was con-
ducted in 55 mild–moderate AD patients with median
area under curve (AUC) of plasma Ab40 concentration
taken between the last IVIg infusion and the final visit as
the primary outcome measure.129 Six groups of between
6 and 8 patients were administered 0.2, 0.5, or 0.8g/kg
IVIg every 4 weeks, or half these doses administered
every 2 weeks, for 24 weeks. In this study, there was no
significant increase in Ab40 AUC following IVIg treat-
ment at any dose; there was a significant decrease in the
0.4g/kg/2 weeks group.
An unpublished 6-month, double-blind, placebo-
controlled study in 24 mild–moderate AD patients
reported an improvement in the clinician global assess-
ment scale in treated patients. Patients were entered into
a 3-year open-label extension, and 4 patients who had
received 0.4g/kg/2 weeks showed no further decline over
this period.
In summary, the preclinical data did not offer
much support for therapeutic efficacy for IVIg, although
the nature of the drug made this a challenging prospect.
The open-label phase 2 data gave a suggestion of a very
small, acute increase in plasma Ab following IVIg treat-
ment. The randomized, placebo-controlled phase 2 stud-
ies, again in small numbers of patients, did not reveal
the expected biomarker response.
GAMMAGARD PHASE 3 TRIAL. Gammagard IVIg was
tested in the Gammaglobulin Alzheimer’s Partnership
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160701 study, a multicenter, randomized, placebo-
controlled phase 3 trial in 390 mild–moderate AD patients
(ClinicalTrials.gov identifier NCT00818662). The trial
examined 2 doses of 0.2g/kg/2 weeks and 0.4g/kg/2weeks
versus placebo for 18 months. IVIg failed to reach its
coprimary outcomes, which were the 18-month change
from baseline on the ADAS-cog and ADCS-ADL. This
study is currently unpublished, and there has been no con-
firmation of whether large increases in plasma Ab as a con-
sequence of antibody capture, as was demonstrated for
solanezumab as a biomarker response, were seen with IVIg.
Conclusion
The amyloid hypothesis has significantly influenced drug
discovery and development in AD over the past 20
years,130 but no amyloidocentric therapeutic agent has
reached its primary outcome measures. This has led
some in the field to question its validity. We are yet to
understand the role (if any) of deposited amyloid, or
other Ab species, in AD. Does Ab act to trigger a disease
that becomes Ab independent, is some threshold level of
brain Ab elevation required, or does Ab drive pathologi-
cal processes in a continuous fashion at all stages of the
disease? Without insight into these fundamental ques-
tions, it is difficult to determine what constitutes a clini-
cal test of the amyloid hypothesis. Our view is that if a
therapeutic agent was able to prevent or significantly
delay Ab deposition without affecting the incidence of
dementia, then the hypothesis as we understand it would
be invalid. We do not discount the possibility that signif-
icantly reducing levels of Ab in the context of pre-
existing deposition may be beneficial; the therapies that
we have reviewed have not achieved this level of efficacy.
In an ideal world, drug discovery can operate in a
stepwise fashion from preclinical to clinical experiments
(Fig 2). Data from each segment of the drug discovery
process is used to predict and interpret outcomes at the
subsequent phase; thus, each activity has a translational
value for the next step. As this schema is target and drug
dependent, aspects of it are not relevant for some of the
therapeutic approaches that we have reviewed; but the
principle of logical progression remains important. Figure
3 provides a guide for how robust the data were to sup-
port the compound progression for each of the therapeu-
tic approaches discussed. In several cases, there were
significant gaps in the data. The best outcome for a
phase 3 trial is that the therapeutic agent provides mean-
ingful clinical benefit with acceptable safety; the worst
outcome is that the therapeutic agent has no clinical ben-
efit (or worsens disease outcomes) but does not unequiv-
ocally test the mechanistic approach, because target
engagement was not measured. For the majority of the
therapeutic agents analyzed, target engagement was not
established. For tramiprosate, data supporting the pri-
mary hypothesis of an antiaggregatory effect on Ab were
weak and not replicated by other laboratories. The in
vivo data were also mixed, with a lack in 1 case of quan-
titative estimates of insoluble Ab, and in another a very
large dose of tramiprosate was administered to demon-
strate a reduction in insoluble Ab that also showed a
reduction in soluble Ab as well; this would not have
been expected for an Ab aggregation inhibitor. Further-
more, dose–response relationships were not established.
The rationale for the choice of clinical doses is not clear,
but nonetheless a reduction in CSF Ab was demonstrated
in the phase 2 studies, although for this mechanistic
FIGURE 2: Many drug discovery programs progress through a logical sequence where the findings from one type of experi-
ment inform the next step. Significant confidence is generated in programs where the data generated within each phase are
concordant with subsequent phases. Programs that lack this translational quality are subject to increasing risk of failure. Drug
Candidate is a therapeutic drug approach with sufficient safety and efficacy data to be administered to man.
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approach an increase in CSF Ab would have been antici-
pated, unless the therapeutic agent was able simultane-
ously to reduce aggregation and increase clearance, for
which mechanistic support is lacking. In the phase 3
study, unanticipated variance precluded a full analysis of
the trial, although there was no evidence for clinical ben-
efit, and proof of mechanism biomarkers (eg, CSF Ab)
are not available. In summary, given the preclinical data,
it is not surprising that tramiprosate failed. For tarenflur-
bil, the preclinical in vitro data demonstrating that the
compound acted as a c-secretase modulator were robust,
but the in vivo data demonstrating effects on brain Ab
levels in tg2576 transgenic mice were not convincing,
and tarenflurbil did not penetrate the brain at a sufficient
concentration to mediate its pharmacological effect,
either in the experiments performed in tg2576 transgenic
mice or in man. Given this, it is not surprising that tar-
enflurbil did not demonstrate efficacy in man, although
it would have been informative to have measured the Ab
metabolite spectrum in the CSF of patients who received
the drug to confirm whether the therapeutic mechanism
of action—a decrease in the longer forms of Ab—had
been achieved. The preclinical and clinical development
of semagacestat was robustly prosecuted, although it is
notable that there were very few subchronic in vivo stud-
ies performed to investigate the effects of the compound
in therapeutic and preventative dosing regimens. Target
engagement was definitively established in man, although
given the mechanism and attendant Notch inhibition it
was clear that the compound’s therapeutic window was
FIGURE 3: The key findings at each phase of the drug discovery process are summarized. These data must be seen in the con-
text that all drug discovery programs, even those where each phase translates robustly into the following phase, are risky.
Considerable judgement must be used during the program: for example, the interpretation of efficacy findings in transgenic
mice and how well these may, or may not, translate to humans. Key: green5 robust data support progression to next step; yel-
low5 incomplete/inconsistent data indicate that progression involves significant risk; red5 available data do not support pro-
gression; white5no data/not applicable. AD5Alzheimer disease; ADAS-cog5Alzheimer’s Disease Assessment Scale–
Cognitive Subscale; ADCS-ADL5Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory; APP5amyloid
precursor protein; ARIA5 amyloid-related imaging abnormality; CDR-SB5Clinical Dementia Rating–Sum of Boxes; CSF5 cere-
brospinal fluid; DAD5Disability Assessment for Dementia; EC505median effective concentration; IVIg5 intravenous immuno-
globulin G; SILK5 stable isotope kinetic effect.
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limited. The unexpected worsening of AD in treated
patients, although very unfortunate, has at least closed
this avenue of therapeutic enquiry; in this sense, the
Identity trials were highly informative. The development
of Gammagard represented a repurposing of an existing
therapeutic agent. The preclinical and clinical data sup-
porting the phase 3 program were insubstantial, and it is
not surprising that Gammagard failed to provide clinical
efficacy. Bapineuzumab was perhaps the most disappoint-
ing of the current phase 3 failures. There were a wealth
of excellent preclinical in vivo data on the compound,
although from the analysis performed herein it is also
clear that the question of whether bapineuzumab (or the
mouse progenitor 3D6) was able to remove existing pla-
que in a therapeutic dosing paradigm was not demon-
strated, with the balance of data suggesting that it could
not. The doses used in the clinical program were limited
by ARIA, and finally the compound failed to show effi-
cacy. Given the uncertainty regarding target engagement,
we believe that the therapeutic benefit of clearing depos-
ited plaque from the brains of AD patients remains to be
tested. Although the preclinical in vivo data demonstrat-
ing the peripheral sink effect for solanezumab were very
robust, and the translation into clinical doses was con-
gruent, the data supporting an effect on clearance of
deposited Ab were weak. These data were also con-
founded somewhat because m266 recognizes both human
and mouse Ab, but nevertheless there is no evidence
from the Expedition trials that solanezumab has an effect
on Ab plaque as measured using amyloid PET imaging.
Thus, the beneficial clinical effects in mild AD—if repli-
cated in Expedition 3—are extremely important both in
providing a new therapeutic agent for AD and also in
providing mechanistic data on the disease process
itself.116
With hindsight, it is easy to pick out the gaps in
data or logic in the programs that we have reviewed, but
some of the inconsistencies were known at the time. The
field is desperate to find a disease-modifying therapeutic
agent for AD, which provides a powerful motivation for
drug developers to sustain drug development programs.
Furthermore, it is clear that the in vivo models we have
are imperfect and of unknown predictive value to human
disease. However, it is surprising that given the massive
costs of clinical studies, the preclinical data are often rela-
tively sparse. It is important that the field learns from the
history of the development of amyloidocentric therapeutic
agents so as to increase our chances of success in the
future. In particular, drug developers should be encour-
aged to make all clinical data rapidly available so as to bet-
ter inform the field. From our analysis, some of these
lessons are quite simple: ensure full dose responses are
measured in in vitro and in vivo systems; check that dose
levels from isolated target, to cell-based assays, to in vivo
experiments, are all sensibly translated; measure the thera-
peutic mechanism of action and target engagement in
humans as early as possible; ensure that biomarker changes
are congruent with the therapeutic mechanism of action;
and do not change the therapeutic hypothesis mid-
development. It also has to be recognized that chronic
dosing experiments in mice can prove challenging because
of the rapid metabolism of test agents, leading either to
low overall exposures or to the requirement for more com-
plex dosing regimens to sustain drug levels. Furthermore,
simple replication of the preclinical experiments with
appropriately powered group sizes and prespecified end-
points, in particular for in vivo experiments, would greatly
enhance the quality of information needed to move thera-
peutic agents into—or out of—the clinical arena. Finally,
an understanding of how the various transgenic mouse
models of Ab deposition relate to the human disease,
especially with respect to preventative versus therapeutic
treatment regimens, is critically important. Most impor-
tantly, realize that hope is no substitute for hard data.
Finally, it is clear that some of the phase 3 clinical
failures that we have reviewed were very unlikely to suc-
ceed. The latest trials of bapineuzumab and solanezumab
provide tantalizing clues with respect to biomarker
changes and clinical efficacy that remain challenging to
interpret.116 The field also awaits with great interest the
progress of the phase 3 trials of MK-8931, a Beta-amy-
loid cleaving enzyme inhibitor that will inhibit the pro-
duction of Ab. MRK-8931 is being tested in prodromal
AD (ClinicalTrials.gov identifier NCT01953601), where
the primary outcome measure is the change from base-
line CDR-SB at 2 years, and in mild–moderate AD
(ClinicalTrials.gov identifier NCT01739348), where the
coprimary outcome measures are a change from baseline
in ADAS-cog and ADCS-ADL at 78 weeks.
Several studies are underway that seek to affect amy-
loid deposition at much earlier stages of AD.131 The Alz-
heimer’s Prevention Initiative has enrolled members of a
large Columbian cohort who carry the E280A PS-1 muta-
tion and will develop AD. Two hundred mutation carriers
within 10 years of predicted cognitive decline will receive
either crenezumab, an anti-Ab antibody, or placebo for 5
years, with the primary endpoint being a composite cogni-
tive test. The Dominantly Inherited Alzheimer’s Network
includes 160 FAD mutation carriers who are cognitively
normal, or with very mild memory complaints who will
receive gantenerumab, an anti-Ab antibody, solanezumab,
or placebo for 2 years followed by a biomarker study to
select the most efficacious drug for a further 3-year trial
with a cognitive endpoint. The Anti-Amyloid Treatment
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in Asymptomatic Alzheimer’s Disease study will recruit
1,000 cognitively normal individuals who have tested posi-
tive on amyloid PET brain scans. They will receive solane-
zumab for 3 years, followed by a 2-year extension period
with the Preclinical Alzheimer’s Cognitive Composite test
as a primary outcome measure. These studies will provide
a wealth of cognitive and biomarker data.
These trials, and the hints of efficacy in mild AD
demonstrated by solanezumab, provide sustenance to
those drug developers and scientists who believe that the
amyloid hypothesis has yet to be tested and that ulti-
mately the field will refute the null hypothesis to provide
effective therapies for this devastating disease.
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